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E-mail address: hmakinos@m.tains.tohoku.ac.jp (HMesenchymal stromal cells (MSCs) have a critical role in cancer progression and metastasis. Despite
extensive studies of the physiological responses in cancer cells, the molecular mechanisms regulat-
ing gene expression in MSCs by cancer cells remain undeﬁned. Here we demonstrate that CC chemo-
kine ligand 5 (CCL5) expression was increased in MSCs co-cultured with pancreatic cancer cells
(PCCs), and this activation was dependent on extracellular insulin-like growth factor (IGF-I).
Moreover, CCL5 induction in MSCs was required for the activation of IGF-I pathway in PCCs. These
results reveal a link between the IGF-I pathway in PCCs and CCL5 pathway in MSCs through the
interaction of those cells.
 2009 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Cancers are a heterogeneous cellular population whose growth
is dependent upon reciprocal interactions between tumor cells and
their dynamic microenvironment [1,2]. The cancer microenviron-
ment includes stromal cells such as tumor associated ﬁbroblasts
(TAFs). The investigation of the cross-talk between cancer cells
and TAFs is important for understanding cancer biology [3–6].
Bone marrow transplantation experiments have suggested that
subsets of TAFs are derived from bone marrow [7–9]. Although
the cellular origin of TAFs has not been conclusively established,
it has been shown that they are most likely derived from mesen-
chymal stromal cells (MSCs) [10–12].
Adult MSCs isolated from bone marrow are known to differen-
tiate into a variety of cell types, including bone, muscle, nerve and
adipose [13–15]. The ability of MSCs to self-renew and differenti-
ate makes them a promising avenue for clinical applications inchemical Societies. Published by E
lls; TAFs, tumor associated
PCCs, pancreatic cancer cells;
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. Makinoshima).regenerative medicine [16]. In mouse models, MSCs could migrate
from bone marrow to the primary tumors and to metastatic sites,
and secrete a variety of soluble factors to activate cancer cell
property [7–9].
The type-I insulin-like growth factor (IGF) system consists of
two ligands (IGF-I and IGF-II), two receptors (IGF-IR and IGF-IIR),
and six binding proteins (IGFBP1–6) that regulate normal
growth and development [17,18]. Substantial evidence indicates
that IGF signaling plays an important role in a variety of human
cancers. The IGF-IR is frequently overexpressed in cancer, and
therapeutic agents targeting IGF-IR are currently in development
[18,19].
Inﬂammatory chemokines have important roles in cancer
malignancy through the heterotypic signaling between cancer
cells and stromal cells [10]. One recent study demonstrated that
the secretion of CC chemokine ligand 5 (CCL5) from MSCs was
dramatically increased by co-culture with breast cancer cells
(BCCs) and that this secretion promoted breast cancer metastasis
[20]. This ﬁnding emphasizes the need to study these cells further
in vitro in order to understand the cellular interactions within the
tumor microenvironment and facilitate development of important
therapeutic interventions to control tumor growth. Despite
extensive studies of cancer cell physiological responses, the
molecular mechanisms controlling gene expression in MSCs are
still unknown.lsevier B.V. All rights reserved.
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2.1. Cell culture
The use of human cells was approved by the Research Ethics
Committee of the Tohoku University. Human MSCs were obtained
from Sunbio Inc. (CA, USA) and maintained for 4–12 passages in
aMEM (Sigma–Aldrich) containing 15% fetal bovine serum (FBS,
MP Biomedicals) and kanamycin on cell culture dishes (Nunc) at
37 C with 5% carbon dioxide. Human pancreatic epithelial cells
(HPECs) were purchased from the Applied Cell Biology Research
Institute (WA, USA) and the PANC-1 cell line was used as pancre-
atic cancer cells (PCCs). All experiments were conducted after
24 h of single or co-culture under each growth condition. The ﬁnal
concentration of PCC culture ﬁltrate (CF) used in experiments was
10%. PCC culture ﬁltrate (CF) was obtained by removing cells with a
0.22 lm syringe ﬁlter (Millipore). MSCs were separated from co-
cultured PCCs by a 0.4 lm Transwell Permeable Support (Corning).
Puriﬁed IGF-I was purchased from R&D Systems Inc. Lentivirus
production was carried out according to the protocols from the
Tronolab (http://tronolab.epﬂ.ch).
2.2. ELISA and Western blot
The culture supernatant was collected from each growth condi-
tion, cells were removed with a 0.22 lm syringe ﬁlter (Millipore)
and CCL5 concentration was determined using an ELISA for human
CCL5 DuoSet Kit (R&D Systems Inc.) according to the manufac-
turer’s protocol. Western blotting was performed as described ear-
lier [21]. After lentivirus infection with the vector for shRNA or
shIGF-IR, total cell lysate was prepared from MSCs and PCCs cul-
tured in complete medium for 72 h. Primary antibodies included
1:1000 dilutions of anti-IGF-IR (R&D) and anti-p-actin (Abcam)
used as loading control.
2.3. Quantitative RT-PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen) and
cDNA was synthesized using the SuperScript VILO cDNA synthesis
kit (Invitrogen). Primers were synthesized and purchased from the
Japan Gene Laboratory (Sendai, Japan). Real-time PCR was per-
formed using a Power SYBR-Green Master PCRMix (Applied Biosys-
tems) and 7300 detection system (Applied Biosystems) intriplicates
[21]. The oligonucleotide sequences previously published [22,23]
are: Forward GAPDH: 50-GACCCCTTCATTGACCTCAAC-30, Reverse
GAPDH: 50-CTTCTCCATGGTGGTGAAGA-30, Forward CCL5: 50-ACCA-
CACCCTGCTGCTTTGC-30, and Reverse CCL5: 50-CCGAACCCATTTCT-
TCTCTGG-30, Forward IGF-IR: 50-TCGACATCCGCAACGACTATC-30,
Reverse IGF-IR: 50-AGGGCGTAGTTGTAGAAGAGTTT-30, respectively.
GAPDH was used for normalization as control and the relative
quantitation value compared to the calibrator for that target is
expressed as 2(Ct–Cc).2.4. Luciferase assay
PCCL5-luc reporter assay with luciferase had previously been re-
ported [24]. The CCL5-promoter-luciferase (PCCL5-luc) construct
was generated by inserting +995 to +36 bp from the translational
initiation site into the pGL3-control vector (Promega), using the
PCR primers, 50-TTGGATCCCAGTATTTATTGAGTTTCC-30 and 50-
GGAAGCTTGGTACCTGTGGGAGAGGCTG-30. Transient transfection
of MSCs was performed using the FuGENE HD transfection reagent
(Roche Diagnostics Systems) according to the manufacturer’s rec-
ommendations. Twenty four hours after lipofection, MSCs were
harvested and 5  103 MSCs, MSCs + HPECs or MSCs + PCCs (1:1)were inoculated in a 24-well culture plate. Luciferase activity
was measured with a Dual luciferase assay (Promega) and lumi-
nescence intensity was acquired using a microplate reader (TECAN,
Austria) at 24 h post co-culture. Columns are the mean of a repre-
sentative experiment assayed in triplicate, normalized to the MSC
level and expressed as fold increase.
2.5. Expression for short hairpin RNA
Short hairpin RNA (shRNA) design was described previously
[25,26]. Brieﬂy, a stem-loop structure oligonucleotide containing
a CCL5-targeting sequence 50-GTGTGTGCCAACCCAGAGA-30 and an
IGF1R-targeting sequence 50-CCGAAGATTTCACAGTCAA-30, was
cloned under the control of the human U6 promoter in lentiviral
vectors (pWPXL, Torono Lab), which also contained a GFP reporter.
The control shVector (shVec) was a no insert loop structure. MSCs
and PCCs were infected with lentivirus for 3 days and conﬁrmed to
be GFP+ by ﬂuorescent microscopy (Nikon). PCCs expressing shVec,
shCCL5 or shIGF-IR were harvested at day 3 and mixed with MSCs
transfected with the PCCL5-luc construct. Luciferase activity was
measured at 24 h.3. Results
3.1. Co-culture of PCCs with MSCs changes colony morphology
To assess whether cancer cells other than BCCs also activated
human MSCs, we analyzed pancreatic cells, either normal HPECs
or the pancreatic cancer cell line PANC-1. Cell morphology was
analyzed using phase contrast and ﬂuorescent microscopy. MSCs
are characterized morphologically by a long spindle and thin cell
body similar to normal ﬁbroblasts (Fig. 1A and G). Normal HPECs
and PCCs form colonies that look like an island characterized by
tight connections with one another on culture dishes (Fig. 1B and
H). When we mixed MSCs with normal HPECs for 24 h, epithelial
cells showed a similar morphology of tight binding to each other
and MSCs occupied the space between the HPECs (Fig. 1C). In con-
trast, the co-culture of MSCs with PCCs changed the angular cancer
cell morphology to a spindle cell shape and disrupted the epithelial
colony morphology to produce scattered individual cells within the
PCCs such that they preferentially attached to MSCs rather than to
PCCs (Fig. 1L). We observed altered cell and colony morphology
more clearly after mixing MSCs with either HPECs or PCCs and
visualizing cells by ﬂuorescent microscopy (Fig. 1D–F and J–L).
Here we conﬁrmed co-culture of PCCs with MSCs changed colony
morphology.
3.2. Co-culture of MSCs with PCCs synergistically activates CCL5
expression
To test whether the pancreatic cancer cell line PANC-I (PCCs)
could also activate CCL5 production in MSCs under co-existing cul-
ture conditions, we measured CCL5 protein levels by ELISA in the
culture medium of MSCs alone, normal HPECs alone, PCCs alone,
and mixed cultures of either MSCs + HPECs (1:1) or MSCs + PCCs
(1:1), respectively. The results showed that co-culture of MSCs
with pancreatic cancer cells speciﬁcally increased CCL5 protein
levels more than 2-fold compared to normal HPECs (Fig. 2A). To
ask if the interaction with pancreatic cancer cells also induced
transcriptional activation of CCL5 in MSCs, we measured CCL5
mRNA levels via quantitative RT-PCR (qRT-PCR). The ratio of CCL5
mRNA showed that there was a synergistic transcriptional increase
following cancer-stroma cross-talk that was approximately 5-fold
higher than that seen during interactions with normal HPECs
(Fig. 2B).
Fig. 1. Co-culture PCCs with MSCs changes colony morphology. (A–C) Phase-contrast photomicrographs show the representative cell and colony morphology of MSCs (A),
normal HPECs (B), and MSCs + HPECs (1:1) (C). Scale bars indicate 100 lm. (D–F) MSCs labeled with GFP (green, 1D), HPECs labeled with mCherry (red, 1E), and mixed
cultures of GFP + MSCs and mCherry+ HPECs at a 1:1 ratio (1F). (G–I) Phase-contrast photomicrographs show the representative cell and colony morphology of MSCs (G), PCCs
(H) and MSCs + PCCs (1:1) (I). Scale bars indicate 100 lm. (J–L) MSCs labeled with GFP (green, 1J), PCCs with mCherry (red, 1K), and mixed cultures of GFP + MSCs and
mCherry+ PCCs at a 1:1 ratio (1L).
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CCL5 expression under co-culture conditions, secreted CCL5 pro-
tein and mRNA could be produced by both PCCs and MSCs. To ver-
ify that the secreted CCL5 in the medium and CCL5 mRNA
expression in the mixed culture was derived from MSCs but not
PCCs, we introduced shRNA against CCL5 to knock down CCL5
expression in PCCs. We successfully reduced the expression of
the CCL5 in PCCs by 50% using shRNA such that ELISA and qRT-
PCR analyses revealed signiﬁcant decreases in CCL5 expression
upon introduction of shCCL5 compared to a control vector under
single cell culture (Fig. 2C and D). In contrast, CCL5 expression at
both the protein and mRNA levels were comparable in the mixed
co-culture condition even in the presence of shCCL5 in PCCs
(Fig. 2C and D). These results suggest that the up-regulation of
CCL5 expression in co-cultures of mixed MSCs and PCCs speciﬁ-
cally occurred in MSCs.
3.3. Expression of CCL5 from the interaction between MSCs and PCCs
requires exogenous growth factors
To further ask whether the activation of CCL5 expression by
PCCs occurred speciﬁcally in MSCs, we constructed a reporter plas-
mid containing luciferase (luc) driven by the CCL5 promoter (PCCL5)
and introduced it into MSCs before mixing transfected cells with
HPECs or PCCs. After the PCCL5-luc reporter plasmid was transfectedinto MSCs, luciferase activity was measured after transfected MSCs
were mixed with PCCs versus normal HPECs (Fig. 3A). Although co-
culture of MSCs with HPECs partially activated PCCL5-luc expression,
co-culture with PCCs dramatically activated PCCL5-luc expression in
MSCs to a level that was 30-fold higher than that induced by HPECs
(Fig. 3A). A synergistic interaction between the MSCs and PCCs
activated PCCL5-luc expression approximately 2000-fold higher than
what was seen in MSCs alone (Fig. 3A). To assess the role of soluble
proteins secreted from PCCs in induction of CCL5 expression, we
measured luciferase activity in MSCs either with or without PCC
culture ﬁltrate (CF), and found that the addition of culture superna-
tant from PCCs didn’t affect MSC PCCL5-luc expression (Fig. 3B, gray
bar). Moreover, this induction required close physical contact
between MSCs and cancer cells, because it failed to occur when
the two cell populations were separated by a 0.4 lm transwell
permeable membrane (Fig. 3B, black bar). This suggested that an
active signal transduction pathway may be triggered in MSCs by
nearby PCCs.
It was possible that extracellular components such as growth
factors could be important for MSC expression of CCL5. To test this
idea, we removed serum from the culture media and measured re-
porter expression as compared to normal cell culture conditions.
Surprisingly, PCCs completely failed to induce PCCL5-luc expression
in MSCs in the absence of FBS, even though PCCs dramatically
up-regulated reporter expression more than 100-fold in the
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um components were required for PCCL5-luc activation in MSCs by
cancer cells. We reasoned that mitogenic growth factors in FBS
could be required for CCL5 expression in MSCs induced by PCCs.
IGF-I is the most abundant growth factor in mineralized bone
matrices and presumably released in the bone marrow cavity [3].
Therefore, we tested whether IGF-I could restore the PCCL5-luc
activity in mixed cultures of PCCs and MSCs in the absence of
FBS. Fig. 3D shows that IGF-I can partially replace the function of
FBS to activate PCCL5-luc expression in MSCs speciﬁcally co-incu-
bated with PCCs such that luciferase activity was approximately
100-fold higher than without IGF-I and more than 50-fold higher
than MSCs alone. Next we asked whether the IGF-I effect for
PCCL5-luc activation was dose-dependent. We observed that the
activation of PCCL5-luc in speciﬁc co-culture conditions declined
with decreasing IGF-I concentration (2–0.02 lg/ml). Dose-depen-
dent enhancement of PCCL5- luc expression was observed upon
exposure to IGF-I in the presence of PCCs over 24 h (Fig. 3E). Alto-
gether, we conclude that IGF-I could restore PCCL5-luc activation
after co-culture of MSCs with PCCs under serum-free conditions.
3.4. Expression of the IGF-I receptor in PCCs is required for the
activation of PCCL5-luc in MSCs in response to extracellular IGF-I
We hypothesized that IGF-I activates either MSCs or PCCs, or
both cell types, through the transmembrane IGF-I receptor (IGF-
IR), which is multifunctional tyrosine kinase that transduces IGFsignals into the intracellular domain [18]. We employed a genetic
approach to characterize the function of the IGF-IR for PCCL5-luc
expression. We fould that we could stably reduce the expression
of the IGF-IR in PCCs by 50% using shRNA such that qRT-PCR for
IGF-IR and Western blot analyses revealed a signiﬁcant decrease
in IGF-IR expression upon introduction of shIGF-IR compared to a
control vector (Fig. 4A and B).
We next measured PCCL5-luc activity using these IGF-IR-down-
regulated PCCs. In the presence of FBS the deletion of the IGF-IR
in PCCs partially impaired PCCL5-luc activation by 50% (Fig. 4C).
The no-serum growth condition failed to stimulate PCCL5-luc activ-
ity in all MSCs even if co-cultured with PCCs (Fig. 4D, gray bar). The
interaction of MSCs with PCCs resulted in a >10-fold higher pro-
duction of luciferase thanMSCs cultured alone with IGF-I or co-cul-
ture of MSCs with PCCs in the absence of IGF-I (Fig. 4D). In contrast,
PCCs with down-regulated IGF-IR could not activate PCCL5-luc acti-
vation compared to vector control (Fig. 4D). This result indicates
that IGF-IR in PCCs is required for full induction of PCCL5-luc expres-
sion by IGF-I in MSCs. These results indicate that the MSC plus PCC
cellular interactions leading to CCL5 expression involve a link be-
tween the IGF-I pathway in PCCs and the CCL5 pathway in MSCs.4. Discussion
We show here that a novel feature of the IGF-I pathway in PCCs
is to stimulate the activation of CCL5 expression in adjacent MSCs
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H. Makinoshima, M. Dezawa / FEBS Letters 583 (2009) 3697–3703 3701triggered by the close association with cancer cells. In MSCs cul-
tured alone in the absence of serum, complementary IGF-I failed
to activate PCCL5-luc expression but additional co-culture with PCCs
could induce expression. These results lead us to hypothesize that
the IGF-I pathway in PCCs through the IGF-IR directly affects gene
expression in MSCs, perhaps by inducing the expression of mole-
cules such as integrins, receptors and cell adhesion molecules in
PCCs. A previous study reported that IGF-I induces the speciﬁctransactivation of the CCL5 receptor CCR5 in BCCs [27]. Another
study indicated that IGF-I stimulates migration of BCCs through
the IGF-IR, and interaction of vitronectin with the avb5 integrin
or collagen with the a2b1 integrin was necessary for the complete
IGF-I response in BCCs [28]. Furthermore, an interesting observa-
tion is that E-cadherin, IGF-IR, and av integrin interact together
to form a ternary complex at cell–cell contact sites [29]. Cell mem-
brane proteins expressed on the surface may facilitate interactions
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3702 H. Makinoshima, M. Dezawa / FEBS Letters 583 (2009) 3697–3703between MSCs and PCCs, and transduce signals into the intracellu-
lar domain to induce gene expression. The exact mechanism
whereby PCCs stimulate stromal CCL5 via direct cell–cell interac-
tion remains to be elucidated.
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